These facts also state the fundamental differences between injectable interferon and our oral interferon. Data from our human clinical trials and our mechanism of action studies show that our low dose oral interferon alpha is biologically, has a systemic effect on the spleen, active and clinically beneficial. . Low dose oral interferon alpha is economically viable. A large portion of the world cannot afford most expensive medical treatments. Low dose oral interferon alpha lends itself to the budget restraints of developing countries.
Clinical trials show few, if any, side effects.
It is patient friendly and non toxic. . It is low-cost and simple to manage. These durable facts are supported with objective data from in vitro and in vivo research, and clinical trials.